Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.

[en] AIMS: Empagliflozin, a sodium-glucose cotransporter type 2 (SGLT2) inhibitor, has been associated with a remarkable reduction in cardiovascular and all-cause mortality in patients with type 2 diabetes and antecedents of cardiovascular disease. This effect was attributed to a diuretic (haemodynamic) rather than metabolic (antiatherogenic) effect. The aim of this review is to offer arguments that either support or challenge this 'diuretic hypothesis'. METHODS: The literature was scrutinized to: (1) examine the diuretic effects of SGLT2 inhibitors vs. hydrochlorothiazide as the reference diuretic; (2) analyze the effects of classic diuretics on cardiovascular outcomes and mortality in diabetic patients; and (3) reconsider some of the specific analyses of the EMPA-REG OUTCOME trial possibly related to a diuretic effect. RESULTS: The diuretic effect of empagliflozin has so far been poorly investigated, although SGLT2 inhibitors have actions distinct from those of classic diuretics. The effects of thiazide-like diuretics on cardiovascular and overall mortality have been limited in diabetic patients with hypertension, whereas the effects of mineralocorticoid receptor antagonists in subgroups of diabetic patients with heart failure were more impressive, but still largely inferior to those reported in EMPA-REG, where relative reductions in mortality with empagliflozin were observed in diabetic patients with or without heart failure, arterial hypertension, renal impairment or diuretic background therapy. CONCLUSION: Although the diuretic hypothesis was put forward to explain the remarkable reduction in mortality with empagliflozin in EMPA-REG, the available results do not support a major contribution of this mechanism, unless the specific diuretic effect of SGLT2 inhibitors turns out to be markedly different from those of classic diuretics.

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Université de Liège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques

Language :

English

Title :

Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.

Publication date :

2016

Journal title :

Diabetes and Metabolism

ISSN :

1262-3636

eISSN :

1878-1780

Publisher :

Masson, Moulineaux Cedex 9, France

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 14 June 2016

Statistics

Number of views

74 (5 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

[1] Scheen, A.J., Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75 (2015), 33–59.
[2] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
[3] Inzucchi, S.E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12 (2015), 90–100.
[4] Ghosh, R.K., Bandyopadhyay, D., Hajra, A., Biswas, M., Gupta, A., Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: a comprehensive review of clinical and preclinical studies. Int J Cardiol 212 (2016), 29–36.
[5] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
[6] Scheen, A.J., Charbonnel, B., Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab 40 (2014), 176–185.
[7] Scheen, A.J., Paquot, N., Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 39 (2013), 179–190.
[8] Wu, J.H., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundstrom, J., et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 4 (2016), 411–419.
[9] Scheen, A.J., Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: a critical analysis. Diabetes Metab 42 (2016), 71–76.
[10] DeFronzo, R.A., The EMPA-REG study: what has it told us? A diabetologist's perspective. J Diabet Complications 30 (2016), 1–2.
[11] Rajasekeran, H., Lytvyn, Y., Cherney, D.Z., Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int 89 (2016), 524–526.
[12] Kimura, G., Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis. J Am Soc Hypertens 10 (2016), 271–278.
[13] Fitchett, D., Zinman, B., Wanner, C., Lachin, J.M., Hantel, S., Salsali, A., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 37 (2016), 1526–1534.
[14] McMurray, J., EMPA-REG – the “diuretic hypothesis”. J Diabet Complications 30 (2016), 3–4.
[15] Sattar, N., McLaren, J., Kristensen, S.L., Preiss, D., McMurray, J.J., SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia, 2016 [Epub ahead of print].
[16] John, M., Empagliflozin: not just a glorified diuretic. Indian J Endocrinol Metab 20 (2016), 154–156.
[17] Tamargo, J., Segura, J., Ruilope, L.M., Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother 15 (2014), 527–547.
[18] Tamargo, J., Segura, J., Ruilope, L.M., Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother 15 (2014), 605–621.
[19] Imprialos, K.P., Sarafidis, P.A., Karagiannis, A.I., Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?. J Hypertens 33 (2015), 2185–2197.
[20] Baker, W.L., Smyth, L.R., Riche, D.M., Bourret, E.M., Chamberlin, K.W., White, W.B., Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 8 (2014), 262–275 [e9].
[21] Weber, M.A., Mansfield, T.A., Cain, V.A., Iqbal, N., Parikh, S., Ptaszynska, A., Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 4 (2016), 211–220.
[22] Chilton, R., Tikkanen, I., Cannon, C.P., Crowe, S., Woerle, H.J., Broedl, U.C., et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17 (2015), 1180–1193.
[23] Scheen, A.J., Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet 53 (2014), 213–225.
[24] List, J.F., Woo, V., Morales, E., Tang, W., Fiedorek, F.T., Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32 (2009), 650–657.
[25] Devineni, D., Morrow, L., Hompesch, M., Skee, D., Vandebosch, A., Murphy, J., et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obesity Metab 14 (2012), 539–545.
[26] Sha, S., Polidori, D., Heise, T., Natarajan, J., Farrell, K., Wang, S.S., et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obesity Metab 16 (2014), 1087–1095.
[27] Devineni, D., Vaccaro, N., Polidori, D., Rusch, S., Wajs, E., Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Clin Ther 36 (2014), 698–710.
[28] Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., Leslie, B., List, J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15 (2013), 853–862.
[29] Amin, N.B., Wang, X., Mitchell, J.R., Lee, D.S., Nucci, G., Rusnak, J.M., Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab 17 (2015), 805–808.
[30] Takeuchi, T., Dohi, K., Omori, T., Moriwaki, K., Sato, Y., Nakamori, S., et al. Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure. Int J Cardiol 201 (2015), 1–3.
[31] Johnsson, K., Johnsson, E., Mansfield, T.A., Yavin, Y., Ptaszynska, A., Parikh, S.J., Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials. Postgrad Med, 2016, 1–10.
[32] Toto, R.D., Wanner, C., Gerich, J., et al. No overall increase in volume depletion events with empagliflozin (EMPA) in a pooled analysis of more than 11,000 patients with type 2 diabetes (T2DM). J Am Soc Nephrol, 24, 2013 [Abstract].
[33] Parveen, R., Agarwal, N.B., Kaushal, N., Mali, G., Raisuddin, S., Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. Expert Opin Pharmacother 17 (2016), 105–115.
[34] Yavin, Y., Mansfield, T.A., Ptaszynska, A., Johnsson, K., Parikh, S., Johnsson, E., Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis. Diabetes Ther 7 (2016), 125–137.
[35] Grossman, E., Verdecchia, P., Shamiss, A., Angeli, F., Reboldi, G., Diuretic treatment of hypertension. Diabetes Care 34:Suppl. 2 (2011), S313–S319.
[36] McGaughey, T.J., Fletcher, E.A., Shah, S.A., Impact of antihypertensive agents on central systolic blood pressure and augmentation index: a meta-analysis. Am J Hypertens 29 (2016), 448–457.
[37] Moura, C.S., Daskalopoulou, S.S., Levesque, L.E., Bernatsky, S., Abrahamowicz, M., Tsadok, M.A., et al. Comparison of the effect of thiazide diuretics and other antihypertensive drugs on central blood pressure: cross-sectional analysis among nondiabetic patients. J Clin Hypertens (Greenwich) 17 (2015), 848–854.
[38] Lievre, M., Gueyffier, F., Ekbom, T., Fagard, R., Cutler, J., Schron, E., et al. Efficacy of diuretics and beta-blockers in diabetic hypertensive patients. Results from a meta-analysis. Diabetes Care 23:Suppl. 2 (2000), B65–B71.
[39] Curb, J.D., Pressel, S.L., Cutler, J.A., Savage, P.J., Applegate, W.B., Black, H., et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 276 (1996), 1886–1892.
[40] Kostis, J.B., Wilson, A.C., Freudenberger, R.S., Cosgrove, N.M., Pressel, S.L., Davis, B.R., et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95 (2005), 29–35.
[41] Whelton, P.K., Barzilay, J., Cushman, W.C., Davis, B.R., Iiamathi, E., Kostis, J.B., et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165 (2005), 1401–1409.
[42] Weber, M.A., Bakris, G.L., Jamerson, K., Weir, M., Kjeldsen, S.E., Devereux, R.B., et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 56 (2010), 77–85.
[43] Sica, D.A., Carter, B., Cushman, W., Hamm, L., Thiazide and loop diuretics. J Clin Hypertens. (Greenwich) 13 (2011), 639–643.
[44] Roush, G.C., Ernst, M.E., Kostis, J.B., Tandon, S., Sica, D.A., Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension 65 (2015), 1041–1046.
[45] Patel, A., MacMahon, S., Chalmers, J., Neal, B., Woodward, M., Billot, L., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007), 829–840.
[46] Gilbert, R.E., Krum, H., Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 385 (2015), 2107–2117.
[47] Duarte, K., Monnez, J.M., Albuisson, E., Pitt, B., Zannad, F., Rossignol, P., Prognostic value of estimated plasma volume in heart failure. JACC Heart Failure 3 (2015), 886–893.
[48] Garg, R., Rao, A.D., Baimas-George, M., Hurwitz, S., Foster, C., Shah, R.V., et al. Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes 64 (2015), 236–242.
[49] Gravez, B., Tarjus, A., Jaisser, F., Mineralocorticoid receptor and cardiac arrhythmia. Clin Exp Pharmacol Physiol 40 (2013), 910–915.
[50] Bapoje, S.R., Bahia, A., Hokanson, J.E., Peterson, P.N., Heidenreich, P.A., Lindenfeld, J., et al. Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail 6 (2013), 166–173.
[51] Chen, M.D., Dong, S.S., Cai, N.Y., Fan, M.D., Gu, S.P., Zheng, J.J., et al. Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis. BMC Cardiovasc Disord, 16, 2016, 28.
[52] Muravyov, A.V., Yakusevich, V.V., Kabanov, A.V., Petrochenko, A.S., The effect of diuretics on red blood cell microrheological parameters in female hypertensive patients. Clin Hemorheol Microcirc 33 (2005), 121–126.
[53] Oh, J., Kang, S.M., Hong, N., Youn, J.C., Han, S., Jeon, E.S., et al. Hemoconcentration is a good prognostic predictor for clinical outcomes in acute heart failure: data from the Korean Heart Failure (KorHF) Registry. Int J Cardiol 168 (2013), 4739–4743.
[54] Vaduganathan, M., Greene, S.J., Fonarow, G.C., Voors, A.A., Butler, J., Gheorghiade, M., Hemoconcentration-guided diuresis in heart failure. Am J Med 127 (2014), 1154–1159.
[55] Palmer, B.F., Metabolic complications associated with use of diuretics. Semin Nephrol 31 (2011), 542–552.
[56] Zhao, G., Huang, L., Song, M., Song, Y., Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis 231 (2013), 61–68.
[57] Jordan, J., Tank, J., Heusser, K., Heise, T., Wanner, C., Heer, M., et al. Empagliflozin has no discernible effect on muscle sympathetic nerve activity in patients with type 2 diabetes despite reductions in blood pressure and weight. Diabetes, 63, 2014, A265 [abstract 1030-P].
[58] Tarnow, L., Gall, M.A., Hansen, B.V., Hovind, P., Parving, H.H., Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 49 (2006), 2256–2262.
[59] Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., et al. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol 11 (2014), 413–426.
[60] Muskiet, M.H., van Raalte, D.H., van Bommel, E., Smits, M.M., Tonneijck, L., Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol 3 (2015), 928–929.
[61] Scheen, A.J., Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Clin Pharmacokinet 54 (2015), 691–708.
[62] Gilbert, R.E., SGLT-2 inhibition in patients with kidney disease. Diabetes Metab 40:6 Suppl. 1 (2014), S23–S27.
[63] Thomas, M.C., Jandeleit-Dahm, K., Bonnet, F., Beyond glycosuria: exploring the intrarenal effects of SGLT(-)(2) inhibition in diabetes. Diabetes Metab 40:6 Suppl. 1 (2014), S17–S22.
[64] Heise, T., Mattheus, M., Woerle, H.J., Broedl, U.C., Macha, S., Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study. Clin Ther 37 (2015), 793–803.